Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Pain’s Toll: Frailty Risk for Childhood Cancer Survivors
2.
Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer
3.
Chemo causes lasting physical decline in breast cancer survivors
4.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
5.
FDA Approves Novel Targeted Therapy for Rare Blood Cancer
1.
Integrated Trends in Hematology for Modern Medicine
2.
The Benefits and Risks of Transurethral Resection of Bladder Tumor
3.
Uncovering the Causes of Thrombocytosis: A Journey to Improved Health
4.
Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management
5.
MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge